Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APL-1202 plus Tislelizumab as Neoadjuvant Therapy for MIBC
NCT04813107Phase 2Unknown
- Sponsor
- Asieris Pharmaceuticals
- Start
- Dec 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of nitroxoline in muscle-invasive bladder cancer (MIBC) (2 arms), sponsored by Asieris Pharmaceuticals. Primary endpoints: Recommended Phase 2 Dose at 9 weeks, Pathologic Complete Response at 26 months and 1 more. Status: unknown.
02
Drugs
nitroxoline
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT04813107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04813107.